Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5209-5215

  Marjuki, Henju ^a   Mishin, Vasiliy P ^a   Sleeman, Katrina ^a   Okomo Adhiambo, Margaret ^a   Sheu, Tiffany G ^a,b   Guo, Lizheng ^a   Xu, Xiyan ^a   Gubareva, Larisa V ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

ANTIGENIC VARIATION; ANTIGENICITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BIOLUMINESCENCE; BIOLUMINESCENCE BASED NEURAMINIDASE INHIBITION ASSAY; CHEMOLUMINESCENCE; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; IC 50; IMMUNOFLUORESCENCE TEST; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VIRUS; INFLUENZA VIRUS B; INTERMETHOD COMPARISON; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; VIRUS CULTURE; VIRUS DETECTION; VIRUS ISOLATION; VIRUS STRAIN; WILD TYPE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME ASSAYS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; KINETICS; LUMINESCENT MEASUREMENTS; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; OSELTAMIVIR; PROTEIN BINDING; VIRAL PROTEINS; ZANAMIVIR;

EID: 84885902295     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01086-13     Document Type: Article

References (37)

1. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. 2003. High frequency of resistant viruses harboring different mutations in amantadine-Treated children with influenza. J. Infect. Dis. 188:57-61.
2. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, Sato I. 2003. Emergence of amantadine-resistant influenza A viruses: Epidemiological study. J. Infect. Chemother. 9:195-200.
3. Sugaya N, Ohashi Y. 2010. Long-Acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 54:2575-2582.
4. Shetty AK, Peek LA. 2012. Peramivir for the treatment of influenza. Expert Rev. Anti Infect. Ther. 10:123-143.
5. Tisdale M. 2000. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
6. Hurt AC, Okomo-Adhiambo M, Gubareva LV. 2012. The fluorescence neuraminidase inhibition assay: A functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods Mol. Biol. 865:115-125.
7. Okomo-Adhiambo M, Hurt AC, Gubareva LV. 2012. The chemiluminescent neuraminidase inhibition assay: A functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods Mol. Biol. 865:95-113.
8. Carr S, Ilyushina NA, Franks J, Adderson EE, Caniza M, Govorkova EA, Webster RG. 2011. Oseltamivir-resistant influenza A and B viruses pre-And postantiviral therapy in children and young adults with cancer. Pediatr. Infect. Dis. J. 30:284-288.
9. Mohr PG, Geyer H, McKimm-Breschkin JL. 2011. Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors. Antiviral Res. 91:20-22.
10. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:2395-2402.
11. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
12. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442.
13. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, Kashiwagi S. 2006. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: A Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin. Infect. Dis. 43:439-444.
14. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K. 2008. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin. Infect. Dis. 47:339-345.
15. Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW, Barr IG, McKimm-Breschkin JL. 2006. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob. Agents Chemother. 50:1872-1874.
16. Sleeman K, Sheu TG, Moore Z, Kilpatrick S, Garg S, Fry AM, Gubareva LV. 2011. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, U. S. A., 2010-11. Emerg. Infect. Dis. 17:2043-2046.
17. WHO. 2012. WHO working group on surveillance of influenza antiviral susceptibility. Wkly. Epidemiol. Rec. 87(39):369-374.
18. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. 2010. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54:3671-3677.
19. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, Lackenby A, Daniels R, Hay A. 2010. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: A role in virus attachment? J. Virol. 84:6769-6781.
20. Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV. 2010. Host cell selection of influenza neuraminidase variants: Implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 85:381-388.
21. Yang W, Liu X, Peng X, Li P, Wang T, Tai G, James Li X, Zhou Y. 2012. Synthesis of novel N-Acetylneuraminic acid derivatives as substrates for rapid detection of influenza virus neuraminidase. Carbohydr. Res. 359: 92-96.
22. Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV. 2010. Neur-Aminidase inhibitor susceptibility testing in human influenza viruses: A laboratory surveillance perspective. Viruses 2:2269-2289.
23. Gubareva LV, Webster RG, Hayden FG. 2002. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53:47-61.
24. Nguyen HT, Trujillo AA, Sheu TG, Levine M, Mishin VP, Shaw M, Ades EW, Klimov AI, Fry AM, Gubareva LV. 2012. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antiviral Res. 93:381-386.
25. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
26. Shu B, Wu KH, Emery S, Villanueva J, Johnson R, Guthrie E, Berman L, Warnes C, Barnes N, Klimov A, Lindstrom S. 2011. Design and performance of the CDC real-Time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus. J. Clin. Microbiol. 49:2614-2619.
27. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
28. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV. 2010. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob. Agents Chemother. 54:1102-1110.
29. Baker NJ, Gandhi SS. 1976. Effect of Caon the stability of influenza virus neuraminidase. Arch. Virol. 52:7-18.
30. Souza TM, Salluh JI, Bozza FA, Mesquita M, Soares M, Motta FC, Pitrowsky MT, de Lourdes Oliveira M, Mishin VP, Gubareva LV, Whitney A, Rocco SA, Goncalves VM, Marques VP, Velasco E, Siqueira MM. 2010. H1N1pdm influenza infection in hospitalized cancer patients: Clinical evolution and viral analysis. PLoS One 5:e14158. doi:10.1371/journal.pone.0014158.
31. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, St George K, Epperson S, Brammer L, Klimov AI, Bresee JS, Fry AM, Oseltamivir-Resistance Working Group. 2009. Infections with oseltamivir- resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
32. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei IP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D'Souza H, Komadina N, Shaw R, Kelso A, Barr IG. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
33. Meijer A, Lackenby A, Hungnes O, Lina B, van-der Werf S, Schweiger B, Opp M, Paget J, van de-Kassteele J, Hay A, Zambon M. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
34. Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Matsuura S, Nishimura M, Iwaki N, Kashiwagi S. 2009. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: A Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin. Infect. Dis. 49:1828-1835.
35. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, Maeda T, Tanaka O, Doniwa K, Kashiwagi S. 2009. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J. Infect. 59:207-212.
36. Barrett S, Mohr PG, Schmidt PM, McKimm-Breschkin JL. 2011. Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. PLoS One 6:e23627. doi:10.1371/journal.pone.0023627.
37. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: Challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 54:1834-1841.